ELEVANCE HEALTH ($ELV) posted quarterly earnings results on Tuesday, October 21st. The company reported earnings of $6.03 per share, beating estimates of $4.98 by $1.05. The company also reported revenue of $50,087,000,000, beating estimates of $49,863,141,682 by $223,858,318.
You can see Quiver Quantitative's $ELV stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
ELEVANCE HEALTH Insider Trading Activity
ELEVANCE HEALTH insiders have traded $ELV stock on the open market 5 times in the past 6 months. Of those trades, 4 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $ELV stock by insiders over the last 6 months:
- GAIL BOUDREAUX (President and CEO) has made 3 purchases buying 8,500 shares for an estimated $2,438,951 and 0 sales.
- MARK KAYE (EVP & CFO) sold 4,588 shares for an estimated $1,949,074
- SUSAN D. DEVORE purchased 1,200 shares for an estimated $374,580
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
ELEVANCE HEALTH Hedge Fund Activity
We have seen 712 institutional investors add shares of ELEVANCE HEALTH stock to their portfolio, and 799 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- GQG PARTNERS LLC added 1,463,610 shares (+inf%) to their portfolio in Q2 2025, for an estimated $569,285,745
- EDGEPOINT INVESTMENT GROUP INC. removed 1,294,560 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $503,532,057
- SANDERS CAPITAL, LLC added 1,152,440 shares (+24.7%) to their portfolio in Q2 2025, for an estimated $448,253,062
- PRICE T ROWE ASSOCIATES INC /MD/ removed 1,057,358 shares (-11.6%) from their portfolio in Q2 2025, for an estimated $411,269,967
- CAPITAL INTERNATIONAL INVESTORS added 932,142 shares (+16.8%) to their portfolio in Q2 2025, for an estimated $362,565,952
- BLACKROCK, INC. removed 898,312 shares (-4.2%) from their portfolio in Q2 2025, for an estimated $349,407,435
- BEUTEL, GOODMAN & CO LTD. added 753,653 shares (+inf%) to their portfolio in Q2 2025, for an estimated $293,140,870
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
ELEVANCE HEALTH Government Contracts
We have seen $268,986,312 of award payments to $ELV over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PART A/PART B MEDICARE ADMINISTRATIVE CONTRACTOR (MAC) JURISDICTION K (JK): $104,482,669
- J6 A/B MAC SERVICES: $80,339,220
- NEXT GENERATION DESKTOP IGF::OT::IGF: $64,075,990
- SPARC WILL BE THE MAJOR CONTRACT VEHICLE FOR CMS IT SYSTEMS AND SUPPORT HHS OPDIVS CAN ALSO MAKE USE OF SPA...: $9,953,079
- THE CONTRACTOR SHALL PROVIDE SUPPLIES AND/OR SERVICES TO PROVIDE A SINGLE FRONT-END SOLUTION FOR THE SUBMIS...: $4,213,107
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
ELEVANCE HEALTH Congressional Stock Trading
Members of Congress have traded $ELV stock 8 times in the past 6 months. Of those trades, 4 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $ELV stock by members of Congress over the last 6 months:
- REPRESENTATIVE LISA C. MCCLAIN has traded it 3 times. They made 2 purchases worth up to $30,000 on 07/10, 06/24 and 1 sale worth up to $15,000 on 08/13.
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 3 times. They made 2 purchases worth up to $30,000 on 08/05, 04/29 and 1 sale worth up to $15,000 on 05/30.
- REPRESENTATIVE ROBERT BRESNAHAN sold up to $50,000 on 05/15.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 05/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
ELEVANCE HEALTH Analyst Ratings
Wall Street analysts have issued reports on $ELV in the last several months. We have seen 7 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 10/09/2025
- Guggenheim issued a "Buy" rating on 10/08/2025
- UBS issued a "Buy" rating on 09/05/2025
- Wells Fargo issued a "Overweight" rating on 08/15/2025
- JP Morgan issued a "Overweight" rating on 07/22/2025
- Truist Securities issued a "Buy" rating on 07/16/2025
- RBC Capital issued a "Outperform" rating on 06/04/2025
To track analyst ratings and price targets for ELEVANCE HEALTH, check out Quiver Quantitative's $ELV forecast page.
ELEVANCE HEALTH Price Targets
Multiple analysts have issued price targets for $ELV recently. We have seen 14 analysts offer price targets for $ELV in the last 6 months, with a median target of $396.5.
Here are some recent targets:
- Erin Wright from Morgan Stanley set a target price of $359.0 on 10/14/2025
- Scott Fidel from Goldman Sachs set a target price of $343.0 on 10/14/2025
- Kevin Fischbeck from B of A Securities set a target price of $370.0 on 10/10/2025
- Andrew Mok from Barclays set a target price of $395.0 on 10/09/2025
- Ann Hynes from Mizuho set a target price of $420.0 on 10/09/2025
- Jason Cassorla from Guggenheim set a target price of $398.0 on 10/08/2025
- Stephen Baxter from Wells Fargo set a target price of $412.0 on 10/07/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
